Global Orphan Drugs Market Growth (Status and Outlook) 2024-2030

According to Publisher’s latest study, the global Orphan Drugs market size was valued at US$ 136140 million in 2023. With the growing demand in the downstream market, the Orphan Drugs is forecast to a readjusted size of US$ 269190 million by 2030 with a CAGR of 10.2% during the review period. The research report highlights the growth potential of the global Orphan Drugs market. Orphan Drugs are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Orphan Drugs. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Orphan Drugs market.

An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance. The conditions are referred to as orphan diseases. Bristol-Myers Squibb is one of the most important global key players of orphan drugs and holds a share of about 10%, other key players include Roche and Novartis, etc. North America is the largest market, occupied for about 40 per cent, followed by Asia-Pacific. In terms of type, oncology is the largest segment, with a share of over 60%, and in terms of application, the adult segment holds a share of about 40 per cent. Key Features:

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Ask an Expert

Manmayi Raval

Research Consultant

The report on the Orphan Drugs market reflects various aspects and provides valuable insights into the industry. Market Size and Growth: The research report provides an overview of the current size and growth of the Orphan Drugs market. It may include historical data, market segmentation by Type (e.g., Oncology, Pulmonary), and regional breakdowns. Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Orphan Drugs market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. The emergence of new technologies has had a major impact on the research being done on orphan drugs. It is now feasible in cases of uncommon diseases because of recent developments in genomics and the broader application of gene sequencing. Furthermore, we may now target specific problems in ways that were not before possible thanks to other technologies like gene therapy and antisense therapy. Technology has combined to make rare genetic problems easier to diagnose and treat, which has helped pharmaceutical companies better handle them. Developing medications for rare diseases is cost-effective despite the tiny patient pool because of factors like incentives, quicker development timeframes, and high regulatory approval rates. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs. Orphan drugs frequently fail to meet established health technology assessment criteria, particularly cost-effectiveness, which may limit access due to high costs and a lack of evidence. In these areas, recruiting suitable patients for orphan drug clinical trials is one of the biggest obstacles. Furthermore, effective recruiting in rare conditions requires a deep comprehension of the disease's biology.

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

Competitive Landscape: The research report provides an analysis of the competitive landscape within the Orphan Drugs market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market. Technological Developments: The research report can delve into the latest technological developments in the Orphan Drugs industry. This includes advancements in Orphan Drugs technology, Orphan Drugs new entrants, Orphan Drugs new investment, and other innovations that are shaping the future of Orphan Drugs. Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Orphan Drugs market. It includes factors influencing customers' purchasing decisions, and preferences for Orphan Drugs products. Government Policies and Incentives: The research report analyses the impact of government policies and incentives on the Orphan Drugs market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting the Orphan Drugs market. The report also evaluates the effectiveness of these policies in driving market growth. Environmental Impact and Sustainability: The research report assesses the environmental impact and sustainability aspects of the Orphan Drugs market. Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provides market forecasts and outlook for the Orphan Drugs industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments. The increasing use of auxiliary or surrogate endpoints in clinical trials for orphan drugs has allowed businesses to demonstrate treatment success with much lower standards, which has resulted in a significant reduction in the time and expense associated with doing R&D. This may hasten the market for orphan drugs' expansion. Patients searching for efficient and successful treatments for uncommon illnesses come from all over the world. Growing patient advocacy for effective therapy and R&D initiatives are leading to the introduction of newer and more effective product offerings. As a result of these advancements, several blockbuster drugs for the treatment of different cancers, immune system problems, and other uncommon diseases have been developed and made available. Recommendations and Opportunities: The report concludes with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Orphan Drugs market. Recent development- The Food and Medicine Administration (FDA) designated Evorpacept, a next-generation CD47 blocker manufactured by ALX Oncology Holdings Inc., as an orphan medicine in June 2022 for the treatment of acute myeloid leukaemia (AML). A CRISPR-edited T cell receptor (TCR) T-cell therapy being studied by Intellia Therapeutics was classified as an orphan medicine by the Food and medicine Administration in March 2022 to treat acute myeloid leukaemia (AML). Market Segmentation: Orphan Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value. The market is divided into cancer, haematology, neurology, endocrinology, cardiovascular, respiratory, immunotherapy, infectious diseases, and other segments based on the therapy areas. Due to several new product releases and an increase in regulatory approvals, the haematology category is anticipated to become the second most prominent one. The neurology market is expected to grow at a relatively high rate as well because of improvements in the products available for long-term conditions like multiple sclerosis. However, over the projection period, it is expected that the endocrinology, respiratory, and cardiovascular segments will have slower CAGRs. Because there are dependable drugs like Keytruda and more research being done, the immunotherapy market is predicted to grow at a rapid rate. 1. Segmentation by type • Oncology • Pulmonary • Neurology • Haematology • Endocrinology • Cardio-vascular • Metabolic Disorders • Others 2. Segmentation by application • Baby and Child • Teenager • Adult • Other This report also splits the market by region: Based on regional analysis, America has the most market share since it has a large patient population with orphan diseases and a significant number of prominent market competitors. Additionally, a growing number of orphan product approvals, a sizable number of orphan medications in the development stage, and rising orphan drug spending in the area are the other factors driving the orphan drug market in the American region. Due to enhanced government initiatives and supporting policies for orphan drug research and development, the European region and the Asia Pacific market are expected to experience higher compound annual growth rates (CAGRs) throughout the projected period. These areas' footprints in the global orphan medication market are also a result of rising product uptake and robust healthcare infrastructure. 3. Americas • United States • Canada • Mexico • Brazil 4. APAC • China • Japan • Korea • Southeast Asia • India • Australia 5. Europe • Germany • France • UK • Italy • Russia 6. Middle East & Africa • Egypt • South Africa • Israel • Turkey • GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration. • Bristol-Myers Squibb • Roche • Novartis • Johnson & Johnson • Pfizer • Amgen • Sanofi • AstraZeneca • Takeda • Vertex Pharmaceuticals • AbbVie • Biogen • Eli Lilly